Aerie Reports Strong Progress in Retinal Program

Casey Kopczynki, PhD, chief scientific officer, shares how Aerie is applying 12 years of studying Rho kinase to combat retinal disease, including AMD and DR. He also reviews Aerie’s agreement with DSM to employ that company’s polymer in delivering Aerie’s AR-13514. Clinical trials could start within two years.